ATGE

Analyst Note: ATGE (Adtalem Global Education Inc.)

Date: 2026-06-13 Current Price: $98.54

1. Structural Readiness

Conservative Entry: Not yet defined (awaiting confirmed breakout) Aggressive/Pre-Breakout Entry: N/A (Current price is $98.54; no specific breakout level defined in current data) Breakout Level: Pending confirmation. Extension: N/A (Price has not yet broken out to generate an extension measurement). ATR Context: Current ATR is 4.3% (High). This indicates elevated volatility, which is within the historical "sweet spot" (4–6%) for structural quality, suggesting the setup has sufficient momentum to move but requires careful position sizing.

2. Thesis Layer

Thesis Status: TACTICAL / SETUP-LED Macro Thesis: None named at this date. Analysis: This is not a name driven by a specific secular macro thesis (e.g., "AI in Education" or "Demographic Shift") at this specific point in time. The investment case is strictly setup-led, relying on the quality of the technical structure (the forming coil) combined with the underlying business fundamentals. The conviction must be derived from the strength of the earnings guidance, the expansion of the physical footprint, and the structural alignment of the stock price, rather than a top-down macro narrative.

3. Business Overview

Company: Adtalem Global Education Inc. (ATGE) Industry: Postsecondary Education / Workforce Solutions Business Model: The company operates through three distinct segments delivering workforce and educational solutions:

• Chamberlain: Offers academic degree programs and specialized non-degree coursework in nursing and health professions. It is the primary driver of the company's physical expansion.
• Walden: Focuses on online learning, providing certificates and degrees (bachelor's to doctoral) in fields such as nursing, education, business, and public health.
• Medical and Veterinary: Provides postsecondary education in medical and veterinary sciences.

Supporting Evidence (as of 2026-06-13):

• Revenue & Earnings Guidance: In the May 7, 2026 earnings transcript, management raised full-year revenue guidance to $1.93 billion – $1.945 billion (up from $1.90B–$1.94B) and raised Adjusted EPS guidance to $7.95 – $8.15 (up from $7.80–$8.00).
• Operational Momentum: Management expects Q4 to mirror Q3, with momentum building into the fall enrollment cycle.
• Market Dynamics: The transcript highlighted a structural labor shortage: "roughly 700,000 health care jobs posted every month in the U.S. and only 306,000 unemployed health care workers to fill them."
• Market Position: Chamberlain confers more nursing degrees than any other university in the country.
• Capital Allocation & Expansion: Six new campuses are in active development. The first begins teaching in September, and two have received full regulatory approval since the Investor Day.
• Cash Flow: Trailing 12-month free cash flow grew 17% to $336 million.
• Financial Spine: Forward consensus EPS for FY1 is $7.94 and FY2 is $9.05.

4. Archetype and Conviction

Archetype: Growth Leader Fit: The name fits the "Growth Leader" archetype due to the combination of double-digit free cash flow growth (17%), raised earnings guidance, and aggressive physical expansion (6 new campuses). The business model is supported by a clear labor market imbalance (high demand for healthcare workers vs. low supply of unemployed workers), which management cites as a primary beneficiary.

Valuation & Conviction Stack:

• Thesis Strength: Moderate. The thesis is tactical and operational rather than macro-driven.
• Evidence Quality: High. The evidence includes specific, raised guidance figures, concrete expansion milestones (6 campuses), and strong cash flow metrics.
• Structural Quality: The current ATR of 4.3% (High) suggests the stock has the volatility required for a strong move, fitting the "sweet spot" for structural setups.
• Setup Readiness: Partial. The coil is forming. The price is holding above the support line, but the breakout has not fired. This is a positive signal but not a confirmed entry.
• Rerating Potential: Supported by the FY2 EPS consensus of $9.05, which implies a significant step up from the current FY1 consensus of $7.94, suggesting the market may re-rate the stock if the expansion delivers as expected.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Further upward revisions to Q4 or full-year guidance in subsequent reports.
• Acceleration in the regulatory approval timeline for the remaining new campuses.

What Would Invalidate the Case:

• A significant miss on the raised revenue or EPS guidance.
• Deterioration in enrollment trends during the fall cycle, contradicting management's "momentum building" expectation.

Gaps in Evidence:

• Specific Breakout Level: The exact price level for the breakout (the top of the coil) is not explicitly defined in the provided data, only that the structure is forming.
• Detailed Segment Margins: While total FCF and revenue are provided, specific margin expansion data by segment (Chamberlain vs. Walden) is not detailed in the provided evidence.
• Capex Specifics: While "six new campuses" are mentioned, the specific capital expenditure required to fund these and the impact on near-term FCF is not quantified in the provided text.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Raised FY26 EPS guidance to $7.95-$8.15; 17% growth in trailing 12-month free cash flow to $336 million; structural labor shortage (700k jobs vs 306k unemployed) driving demand for Chamberlain degrees. Key risks: Setup remains in "forming" state without confirmed breakout; regulatory delays on new campus approvals; potential enrollment softness in Q4 if momentum stalls. Sizing hint: Position size should reflect the "forming" status and high ATR (4.3%); maintain a smaller initial size until the breakout fires to manage volatility risk. Expected path: Management expects Q4 to mirror Q3 with momentum building; the six new campuses will begin contributing revenue starting in September, supporting the raised FY26 guidance. Expected horizon: 3 to 6 months to allow the forming coil to resolve into a confirmed breakout or a deeper consolidation.